<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663764</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1042</org_study_id>
    <nct_id>NCT03663764</nct_id>
  </id_info>
  <brief_title>Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma</brief_title>
  <official_title>A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study is to determine the efficacy of thymosin a1 during chemoradiotherapy for
      unresectable thymoma and thymic carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II study is to determine the efficacy of thymosin a1 during chemoradiotherapy for
      unresectable thymoma and thymic carcinoma.

      All patients received four cycles of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of
      1 day's duration, combined with thoracic radiotherapy of 66 Gy/22 fractions. Meanwhile they
      received weekly thymosin a1(1.6mg) during and within 2 months after the end of
      chemoradiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to a 10 point (10%) deterioration in Quality of Life score</measure>
    <time_frame>3 years</time_frame>
    <description>EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer) core questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Thymoma and Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Expeiment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in experimental group received four cycles of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 66 Gy/22 fractions. Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin a1</intervention_name>
    <description>All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.</description>
    <arm_group_label>Expeiment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of thymoma or thymic carcinoma.

          -  Patients have measurable or evaluable lesions based on the Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Unresectable, refusing surgery or after R2 surgery.

          -  Previously treated with chemotherapy or treatment-naive.

          -  No previous chest radiotherapy, immunotherapy or biotherapy.

          -  White blood cell count ≥4×109 /L, neutrophile granulocyte count≥1.5×109 /L, platelet
             count≥100×109 /L, hemoglobin ≥100 g /L, serum creatinine and bilirubin 1.5 times less
             than the upper limits of normal (ULN),aminotransferase two times less than the ULN.

          -  FEV1 &gt;0.8 L

          -  CB6 within normal limits

          -  Patients and their family signed the informed consents

        Exclusion Criteria:

          -  Previous or recent another malignancy, except for nonmelanoma skin cancer or cervical
             cancer in situ.

          -  Already received antineoplastic therapy,including chemotherapy, radiotherapy or
             operation.

          -  Any contraindication for chemotherapy or radiotherapy(such as a myocardial infarction
             within 6 months,immunosuppressive therapy,symptomatic heart disease,including unstable
             angina pectoris, congestive heart failure,and uncontrolled arrhythmia).

          -  Malignant pleural effusion or pericardial effusion.

          -  Weight loss &gt;10% within the past 3 months.

          -  Recruited in other clinical trials within 30 days

          -  Drug addiction, long-term alcohol abuse and AIDS patients.

          -  Uncontrollable epileptic attack or psychotic patients without self-control ability.

          -  Severe allergy or idiosyncrasy.

          -  Not suitable for this study judged by researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Liu, Professor</last_name>
    <phone>+86-020-87343031</phone>
    <email>liuhui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Attending</last_name>
      <phone>+86-020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Liu, Professor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1698-704. doi: 10.1097/JTO.0b013e31821e7b12. Review.</citation>
    <PMID>21847050</PMID>
  </reference>
  <reference>
    <citation>Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1710-6. doi: 10.1097/JTO.0b013e31821e8cff.</citation>
    <PMID>21847052</PMID>
  </reference>
  <reference>
    <citation>Gao L, Wang C, Fang W, Zhang J, Lv C, Fu S. Outcome of multimodality treatment for 188 cases of type B3 thymoma. J Thorac Oncol. 2013 Oct;8(10):1329-34. doi: 10.1097/JTO.0b013e31829ceb50. Erratum in: J Thorac Oncol. 2014 Nov;9(11):1719.</citation>
    <PMID>24457243</PMID>
  </reference>
  <reference>
    <citation>Marx A, Ströbel P, Badve SS, Chalabreysse L, Chan JK, Chen G, de Leval L, Detterbeck F, Girard N, Huang J, Kurrer MO, Lauriola L, Marino M, Matsuno Y, Molina TJ, Mukai K, Nicholson AG, Nonaka D, Rieker R, Rosai J, Ruffini E, Travis WD. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014 May;9(5):596-611. doi: 10.1097/JTO.0000000000000154.</citation>
    <PMID>24722150</PMID>
  </reference>
  <reference>
    <citation>Guerrera F, Rendina EA, Venuta F, Margaritora S, Ciccone AM, Novellis P, Novero D, Anile M, Bora G, Rena O, Casadio C, Mussi A, Evangelista A, Ruffini E, Lucchi M, Filosso PL. Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicentre study on 750 patients. Eur J Cardiothorac Surg. 2015 Jul;48(1):48-54. doi: 10.1093/ejcts/ezu368. Epub 2014 Sep 21.</citation>
    <PMID>25246487</PMID>
  </reference>
  <reference>
    <citation>Onuki T, Ishikawa S, Yamamoto T, Ito H, Sakai M, Onizuka M, Sakakibara Y, Iijima T, Noguchi M, Ohara K. Pathologic radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol. 2008 Mar;3(3):270-6. doi: 10.1097/JTO.0b013e3181653c8c.</citation>
    <PMID>18317070</PMID>
  </reference>
  <reference>
    <citation>Bretti S, Berruti A, Loddo C, Sperone P, Casadio C, Tessa M, Ardissone F, Gorzegno G, Sacco M, Manzin E, Borasio P, Sannazzari GL, Maggi G, Dogliotti L; Piemonte Oncology Network. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer. 2004 Apr;44(1):69-77.</citation>
    <PMID>15013585</PMID>
  </reference>
  <reference>
    <citation>Wright CD, Choi NC, Wain JC, Mathisen DJ, Lynch TJ, Fidias P. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg. 2008 Feb;85(2):385-9. doi: 10.1016/j.athoracsur.2007.08.051.</citation>
    <PMID>18222230</PMID>
  </reference>
  <reference>
    <citation>Korst RJ, Bezjak A, Blackmon S, Choi N, Fidias P, Liu G, Marx A, Wright C, Mock S, Rutledge JR, Keshavjee S. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg. 2014 Jan;147(1):36-44, 46.e1. doi: 10.1016/j.jtcvs.2013.08.061. Epub 2013 Oct 15.</citation>
    <PMID>24139613</PMID>
  </reference>
  <reference>
    <citation>Venuta F, Rendina EA, Pescarmona EO, De Giacomo T, Vegna ML, Fazi P, Flaishman I, Guarino E, Ricci C. Multimodality treatment of thymoma: a prospective study. Ann Thorac Surg. 1997 Dec;64(6):1585-91; discussion 1591-2.</citation>
    <PMID>9436540</PMID>
  </reference>
  <reference>
    <citation>Lucchi M, Mussi A, Basolo F, Ambrogi MC, Fontanini G, Angeletti CA. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg. 2001 May;19(5):566-9.</citation>
    <PMID>11343932</PMID>
  </reference>
  <reference>
    <citation>Rea F, Sartori F, Loy M, Calabrò F, Fornasiero A, Daniele O, Altavilla G. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg. 1993 Sep;106(3):543-9.</citation>
    <PMID>8361199</PMID>
  </reference>
  <reference>
    <citation>Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, Miyazawa N. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol. 2007 Jan;2(1):73-8.</citation>
    <PMID>17410014</PMID>
  </reference>
  <reference>
    <citation>Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007 Sep;1112:1-13. Epub 2007 Jun 28.</citation>
    <PMID>17600284</PMID>
  </reference>
  <reference>
    <citation>Garaci E, Pica F, Sinibaldi-Vallebona P, Pierimarchi P, Mastino A, Matteucci C, Rasi G. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol. 2003 Aug;3(8):1145-50. Review.</citation>
    <PMID>12860169</PMID>
  </reference>
  <reference>
    <citation>Jiang J, Wang X, Tian J, Li L, Lin Q. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. Thorac Cancer. 2011 Nov;2(4):213-220. doi: 10.1111/j.1759-7714.2011.00057.x.</citation>
    <PMID>27755854</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 9, 2018</last_update_submitted>
  <last_update_submitted_qc>September 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Unresectable Thymoma and Thymic Carcinoma</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Thymosin a1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

